T. Hugh Jones

Mar 1, 2024 | healio.com | Michael Monostra |Richard Smith |T. Hugh Jones |Shalender Bhasin

T. Hugh Jones, BSc, MBChB, MD, FRCP The primary outcome of the TRAVERSE study was reported in the New England Journal of Medicine last year. Testosterone therapy was not associated with an increased risk for a major adverse cardiovascular event compared with placebo in this large study that included men with either known CVD or high CV risk, which comprised approximately 70% of men with diabetes.